Story
Shattuck Labs Stock Slides as Wider Loss Overshadows Pipeline Progress

Shattuck Labs (NASDAQ: STTK) shares declined in pre-market trading after the company released second-quarter 2026 financial results that showed a wider net loss and higher research costs, overshadowing positive clinical trial developments.
Financial Performance
The clinical-stage biotechnology firm reported a net loss of $15.2 million for the second quarter, an increase from the $12.5 million net loss recorded in the same period a year ago. According to the earnings report, the wider loss was driven by a significant rise in operating expenses.
Research and development (R&D) expenses climbed 34% year-over-year to $11.7 million, a figure that surpassed analyst expectations. As a pre-revenue company, Shattuck Labs did not report any income for the quarter.
Pipeline and Clinical Updates
Despite the weaker financial metrics, Shattuck Labs provided a constructive update on its drug pipeline. The company announced positive Phase 1 data for its lead candidate, SL-325, an antibody targeting the TL1A pathway. The results indicated a favorable safety profile and durable receptor blockade for more than three months at therapeutic doses.
AdCEO Taylor Schreiber stated that the Phase 1 data "checked all of the boxes," positioning SL-325 competitively for further studies. The company confirmed its Phase 2b trial in Crohn’s disease patients is on track to begin in the current quarter. Shattuck also introduced a new candidate, SL-846, with initial data anticipated in 2027.
Market Context
The stock's decline reflects a common dynamic for development-stage biotech firms, where higher-than-expected spending can weigh on sentiment even amid clinical progress. The pullback also occurred as the stock was trading near its 52-week high, making it susceptible to profit-taking on a mixed report.
However, the company's financial position remains robust. Shattuck Labs ended the quarter with approximately $208.3 million in cash and investments, which it stated provides an operational runway into 2029. This strong balance sheet may provide a floor for the stock as investors assess the long-term potential of its pipeline.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.